QuVa Pharma FDA-483
FDA has released the form FDA-483 issued following a 7/11-8/18/22 inspection at QuVa Pharma, a Sugar Land, TX, outsourcing facility. The three inspection observations were:
- employees engaged in the manufacture and processing of a drug product lack the training required to perform their assigned functions;
- determination of conformance to appropriate written specifications for acceptance of drug products is deficient; and
- the written stability testing program is not followed.